Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Future FinTech Group Inc. - Common Stock
Southern Cross Gold Consolidated Ltd
Edit Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Ensysce Biosciences, Inc. - Common Stock
(NQ:
ENSC
)
0.3600
-0.0006 (-0.17%)
Delayed Quote
Updated: 4:00 PM EST, Nov 20, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Ensysce Biosciences, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
Ensysce Biosciences Announces Participation in Upcoming Investor Conferences
November 16, 2026
From
Ensysce Biosciences
Via
ACCESS Newswire
Ensysce Biosciences Reports Third Quarter 2026 Financial Results and Business Highlights
November 12, 2026
~ Completed Acquisition of Cy Biopharma, Adding Lead Pipeline Asset CY200 for Complex Regional Pain Syndrome ~ ~ Submitted Phase 2a Protocol for CY200 to the UK's Medicines and Healthcare products...
From
Ensysce Biosciences
Via
ACCESS Newswire
Ensysce Biosciences Expands Global Investor and Strategic Outreach at Family Office Summit, Dubai
October 21, 2026
~President James Morrison met Middle East family offices as Ensysce advances CY200 and its severe pain pipeline~
From
Ensysce Biosciences
Via
ACCESS Newswire
Ensysce Biosciences Phase 2 Protocol for CY200 - A Neuroplastigen for the Treatment of CRPS - Submitted to the UK MHRA
September 24, 2026
~ Submission to the UK MHRA for review marks critical step towards initiating a Phase 2 Study with CY200 ~
From
Ensysce Biosciences
Via
ACCESS Newswire
Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study
June 26, 2026
From
Ensysce Biosciences
Via
ACCESS Newswire
Ensysce Biosciences Advances CRPS Program at Painweek 2026, Contributes to FDA Hearing on Psychedelic Drug Regulation
September 15, 2026
From
Ensysce Biosciences
Via
ACCESS Newswire
Ensysce Biosciences' Professor Richard Langford Selected to Speak at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs
September 14, 2026
From
Ensysce Biosciences
Via
ACCESS Newswire
Ensysce Biosciences Announces Upcoming Conference and Industry Event Participation
September 02, 2026
From
Ensysce Biosciences
Via
ACCESS Newswire
Ensysce Biosciences Completes Final Phase of PF614-MPAR-102 Clinical Study
August 31, 2026
From
Ensysce Biosciences
Via
ACCESS Newswire
Ensysce Biosciences to Showcase "A New Era in Pain Therapeutics" at PAINWeek 2026 Symposium
August 20, 2026
From
Ensysce Biosciences
Via
ACCESS Newswire
Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights
August 13, 2026
From
Ensysce Biosciences
Via
ACCESS Newswire
Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing
August 06, 2026
From
Ensysce Biosciences
Via
ACCESS Newswire
The Bull Lives Below $1: PRSO, ENSC, TNMG, QNME Stocks to Watch
August 04, 2026
Via
AB Newswire
Topics
Artificial Intelligence
Ensysce Biosciences Awarded $5.3 Million Installment in NIDA Funding Completing Multi-Year $15 Million Federal Grant
July 14, 2026
From
Ensysce Biosciences
Via
ACCESS Newswire
Ensysce Biosciences Reports First Quarter 2026 Financial Results
May 15, 2026
Via
ACCESS Newswire
Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology
May 12, 2026
Via
ACCESS Newswire
Ensysce Biosciences CEO Presents at Inaugural Clinical Pain Symposium in Amsterdam
May 08, 2026
Via
ACCESS Newswire
Ensysce Biosciences Secures IRB Approval of Final Phase of PF614-MPAR-102 Clinical Study
April 16, 2026
Via
ACCESS Newswire
Ensysce Biosciences Secures Second Financing From 2025 Agreement to Advance Breakthrough Pain Programs
April 07, 2026
Via
ACCESS Newswire
Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results
March 30, 2026
Via
ACCESS Newswire
Ensysce Biosciences Initiates Live "Ask Me Anything" (AMA) Session Highlighting Growth and Future Plans
March 04, 2026
Via
ACCESS Newswire
Ensysce Biosciences Announces First Peer-Reviewed Clinical Publication Demonstrating Oral Overdose Protection with MPAR(R) Technology
March 03, 2026
Via
ACCESS Newswire
Rapid Dose Therapeutics (CSE: DOSE) (OTCQB: RDTCF) Advances QuickStrip™ Research Backed by NFL-Supported Clinical Evaluation – More Stocks Inside
February 27, 2026
Via
AB Newswire
Ensysce Biosciences Initiates Review of Strategic Alternatives to Enhance Shareholder Value
February 25, 2026
Via
ACCESS Newswire
Ensysce Biosciences Invited to Participate in Upcoming Scientific and Industry Events
February 23, 2026
Via
ACCESS Newswire
Ensysce Biosciences Expands Global Opioid Patent Portfolio
January 21, 2026
Via
ACCESS Newswire
Ensysce Biosciences Receives EU Patent Expanding its First-in-Class ADHD Therapy with Built-In Abuse and Overdose Protection
January 08, 2026
Via
ACCESS Newswire
Ensysce Biosciences Issues Annual Shareholder Letter
January 05, 2026
Via
ACCESS Newswire
Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid
December 09, 2025
Via
ACCESS Newswire
Ensysce Biosciences Announces Broader Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology
December 02, 2025
Via
ACCESS Newswire
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1